



FINANCIAL TRUST COMPANY INC ACCT. [REDACTED]

For the Period 2/1/12 to 2/29/12

Note: P indicates position adjusted for Pending Trade Activity.

** Unrealized Gain/Loss is shown as "N/A" in cases where we do not have appropriate cost information for all tax lots comprising the position. Please contact your J.P. Morgan team for additional information.

Equity Detail

	Price	Quantity	Value	Adjusted Tax Cost Original Cost	Unrealized Gain/Loss	Est. Annual Inc. Accrued Div.	Yield
US Large Cap Equity							
ARIAD PHARMACEUTICALS INC 04033A-10-0 ARIA	14.35	16,535.000	237,277.25	251,475.52	(14,198.27)		
BIOGEN IDEC INC 09062X-10-3 BIIB	116.47	2,095.000	244,004.65	250,454.95	(6,450.30)		
DB CONT BUFF EQ MS 08/07/12 25% CONTIN BARRIER- 13%CPN 30% CAP INITIAL LEVEL-07/15/11 MS:21.09 2515A1-A7-6	86.52	1,000,000.000	865,200.00	1,000,000.00	(134,800.00)		
P FIRST REPUBLIC BANK SAN FRAN 33616C-10-0 FRC	29.99			0.00			
HSBC MARKET PLUS SPX 05/17/13 72% KO BARRIER- 0%CPN ,UNCAPPED INITIAL LEVEL-02/14/12 SPX:1350.50 4042K1-XQ-1	100.03	5,000,000.000	5,001,500.00	5,000,000.00	1,500.00		
P ONEOK PARTNERS L.P 68268N-10-3 OKS	58.20			0.00			4.19%

J.P.Morgan

Account W23560001 Page 5 of 33

Consolidated Statement Page 8

Confidential Treatment Requested by JPMorgan
Chase
CONFIDENTIAL

JPM-SDNY-00015634

SDNY_GM_00284832

EFTA01492817